文献速递白血病

低剂量阿糖胞苷联合聚乙二醇化重组精氨酸酶BCT-100对比低剂量阿糖胞苷治疗不适合强化治疗的老年急性髓系白血病患者的随机评估:LI-1试验结果

A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
PubMed 文献 · Br J Haematol · 2022-11-22

该随机研究纳入83例不适合强化治疗的老年急性髓系白血病患者,比较低剂量阿糖胞苷联合BCT-100与单用低剂量阿糖胞苷的疗效。联合组总缓解率19.5%(均为完全缓解),单药组15%(完全缓解和完全缓解伴计数恢复不完整各7.5%),两组总生存或无显著差异,联合治疗耐受良好。

要点

  • 低剂量阿糖胞苷联合BCT-100组总缓解率19.5%,均为完全缓解。
  • 单用低剂量阿糖胞苷组总缓解率15%,完全缓解和完全缓解伴计数恢复不完整各7.5%。
  • 两组总生存或无显著差异,联合BCT-100耐受良好。

核心结论

  • 在老年不适合强化治疗的急性髓系白血病患者中,低剂量阿糖胞苷联合BCT-100与单用低剂量阿糖胞苷相比,总缓解率无显著差异,总生存亦无显著差异,联合治疗耐受良好。

研究设计与样本

  • 随机研究,纳入83例不适合强化治疗的老年急性髓系白血病患者,随机分配至低剂量阿糖胞苷联合BCT-100组或单用低剂量阿糖胞苷组。

主要发现

  • 低剂量阿糖胞苷联合BCT-100组总缓解率为19.5%(均为完全缓解),单用低剂量阿糖胞苷组总缓解率为15%(完全缓解和完全缓解伴计数恢复不完整各7.5%)。
  • 两组总缓解率的比值比为0.73(置信区间0.23-2.33;p=0.592)。
  • 两组总生存或中位生存均无显著差异。
  • 低剂量阿糖胞苷联合BCT-100耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is being made, however, for subgroups with favourable molecular or cytogenetic findings. Arginine metabolism plays a key role in AML pathophysiology. We report the only randomised study of LDAC with recombinant arginase BCT-100 versus LDAC alone in older AML patients unsuitable for intensive therapy. Eighty-three patients were randomised to the study. An overall response rate was seen in 19.5% (all complete remission [CR]) and 15% (7.5% each in CR and CR without evidence of adequate count recovery [CRi]) of patients in the LDAC+BCT-100 and LDAC arms respectively (odds ratio 0.73, confidence interval 0.23-2.33; p = 0.592). No significant difference in overall or median survival between treatment arms was seen. The addition of BCT-100 to LDAC was well tolerated.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mussai F, De Santo C, Cheng P, et al. A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial. Br J Haematol. 2022. PMID: 36413792. doi:10.1111/bjh.18560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。